|
Palo Alto, CA, October 21, 2003 — Telik, Inc. (Nasdaq:
TELK) announced positive interim results from its Phase 1-2a clinical
trial using escalating doses TELCYTA™ in combination with
the standard dose of docetaxel in patients with Stage IIIB or IV
non-small cell lung cancer (NSCLC) who failed prior platinum-based
therapy. At the time of interim analysis, the dose escalation phase
has been completed and 14 patients who received full doses of TELCYTA™
(960 mg/m2) and docetaxel (75 mg/m2) are evaluable. Three of the14
evaluable patients (22%) have objective tumor responses by the RECIST
criteria, with an overall disease stabilization rate of 64%. TELCYTA™
in combination with docetaxel has been well-tolerated in this patient
population. The longest duration of treatment with this combination
is greater than seven months (9+ cycles). The interim results suggest
that TELCYTA™ and docetaxel may be administered in combination
using the full dose of each drug. Patient enrollment and treatment
continue at the full dose level.
These data follow the previously reported single agent anti-tumor
activity of TELCYTA™ confirmed in two Phase 2 trials in NSCLC,
and represent an important step in the product development process
to establish potential use in less advanced cancer patients. Telik
intends to present additional results from this clinical trial at
the American Association of Cancer Research — National Cancer
Institute — European Organization for Research and Treatment
of Cancer - International Conference on Molecular Targets and Cancer
Therapeutics in November 2003.
About Telik, Inc.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™. Telik’s product candidates were discovered
using its proprietary technology, TRAP, which enables the rapid
and efficient discovery of small molecule drug candidates. Additional
information is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding our ability to
successfully develop TELCYTA™ for the treatment of any cancer,
its tolerability, potential efficacy or market potential. Telik
can give no assurance with regard to these statements. None of our
products have been determined to be safe or effective in humans
or been approved for marketing. Substantial additional testing,
including randomized, controlled clinical trials of TELCYTA™
will be necessary prior to seeking marketing approval. There can
be no assurance that such trials will accrue sufficient patients,
be conducted with sufficient quality, in a timely manner, have a
successful outcome, or that regulatory approval will be obtained.
In addition, we are reliant on external manufacturing, and any interruption
or delay in drug supply could adversely affect the development program.
More detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Telik’s
periodic filings with the Securities and Exchange Commission. Telik
assumes no obligation to update any information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
